<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140956</url>
  </required_header>
  <id_info>
    <org_study_id>3112006</org_study_id>
    <nct_id>NCT03140956</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Levodopa Study in Healthy Males</brief_title>
  <official_title>Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate PK of levodopa in plasma after repeated doses of 3
      levodopa formulations given in combination with carbidopa and ODM-104 and compared to the PK
      of standard IR and CR levodopa formulations in the same combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">August 3, 2017</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax) of levodopa</measure>
    <time_frame>24 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa formulation D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa formulation E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa formulation F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation F</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet IR 100/25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet IR 100/25MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet CR 100/25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet IR 100/25MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-104 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ODM-104 100MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbidopa 20MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 65mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbidopa 65MG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa, carbidopa, ODM-104</intervention_name>
    <description>Crossover design. Study treatments will be administered in randomized order 4 times a day.</description>
    <arm_group_label>Levodopa formulation D</arm_group_label>
    <arm_group_label>Levodopa formulation E</arm_group_label>
    <arm_group_label>Levodopa formulation F</arm_group_label>
    <arm_group_label>Sinemet IR 100/25mg</arm_group_label>
    <arm_group_label>Sinemet CR 100/25mg</arm_group_label>
    <arm_group_label>ODM-104 100mg</arm_group_label>
    <arm_group_label>Carbidopa 20mg</arm_group_label>
    <arm_group_label>Carbidopa 65mg</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (IC) obtained.

          -  Finnish speaking males between 18-65 years of age.

          -  Body mass index (BMI) between 19-32 kg/m2 (BMI = weight/height2).

          -  Weight at least 60 kg.

          -  Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or
             other intestinal problems, and no history of major gastrointestinal surgery).

          -  Sexually active study subjects, unless surgically sterile must adhere to a proper form
             of contraception (hormonal contraception or intrauterine device on female partner and
             an additional barrier method used at least by one of the partners) and must not donate
             sperm from the first study treatment administration until 3 months after the last
             study treatment administration.

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease
             or cancer (except local non-melanoma skin cancer) within the previous 2 years.

          -  Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study. As an
             exception, paracetamol for occasional pain is allowed.

          -  Any clinically significant abnormal laboratory value or ECG (such as prolonged QTcF &gt;
             450 ms or QRS &gt; 120 ms) that in the opinion of the investigator could interfere with
             the interpretation of study results or cause a health risk for the subject if he takes
             part in the study.

          -  Known hypersensitivity to the active substances or the excipients of the drugs.

          -  History of vasovagal collapses or vagal reactions with unexplained reason within the
             previous 2 years or a tendency for vasovagal reactions during blood sampling.

          -  HR &lt; 40 beats per minute (bpm) or &gt; 90 bpm in the supine position after 5 min rest at
             the screening visit.

          -  At the screening visit:systolic BP &lt; 90 mmHg or &gt; 150 mmHg in the supine position
             after 5 min rest and diastolic BP &lt; 50 mmHg or &gt; 90 mmHg in the supine position after
             5 min rest.

          -  History of anaphylactic/anaphylactoid reactions.

          -  Strong tendency to motion sickness.

          -  Recent or current (suspected) drug abuse.

          -  Recent or current alcohol abuse; regular drinking of more than 21 units per week (1
             unit = 4 cl spirits or equivalent).

          -  Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day
             and/or inability to refrain from the use of nicotine containing products during the
             study (from the screening visit to the end-of-study visit).

          -  Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability
             to refrain from using caffeine containing beverages 10 h before and during the study
             periods.

          -  Blood donation or loss of a significant amount of blood within 90 days before the
             first study treatment administration.

          -  Participation in an investigational drug study or administration of an investigational
             drug within 90 days before the first study treatment administration.

          -  Unsuitable veins for repeated venipuncture or cannulation.

          -  Predictable poor compliance or inability to communicate well with the study centre
             personnel.

          -  Inability to participate in all treatment periods.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <zip>02200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

